Issue

Vol. 66 No. 7: Issue 7

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Estimation levels of prostate-specific antigen, interleukin-8, oxidative stress and some inflammatory markers in sera of benign prostatic hyperplasia patients who have smoking habits as a risk factor

https://doi.org/10.14715/cmb/2020.66.7.19
Ruqaya Mohammed Ghareeb Taher Al-Barzinj
Unit of Microbioligy, Department of Basic Science, Collage of Medicine, Hawler Medical University, Erbil, Kurdistan Region-Iraq.

Corresponding Author(s) : Ruqaya Mohammed Ghareeb Taher Al-Barzinj

ruqayataher2012@gmail.com

Cellular and Molecular Biology, Vol. 66 No. 7: Issue 7

Abstract

Benign prostatic hyperplasia (BPH) is a common multifactorial inflammatory disease of older men, defined by increased growth of prostate epithelial and stromal cells. Elevation serum levels of Interleukin-8 (IL-8), oxidative stress and inflammatory markers represent predictive surrogate markers of the disease progression in smoker BPH patients. A total of 86 BPH patients and 54 control subjects were admitted to the urology unit, Rizgary Teaching Hospital in Erbil City, Iraq between January and June 2020. Sera levels of prostate-specific antigen(PSA), IL-8, malondialdehyde (MDA), high sensitive C-reactive protein (hs-CRP), testosterone and some biomarkers concentrations were measured in the patients according to instructions of manufacturers. Patients and controls were categorized into groups according to smoking status (smokers and non-smokers). The sera levels of PSA, IL-8 and inflammatory markers like oxidative stress(MDA), hs-CRP and testosterone in every smoker subgroup (BPH patients and control) increased compared to the same non-smoker subgroups and significantly increased compared with non-smoker control (p<0.05). PSA demonstrated a significant positive correlation with the following terms, IL-8, MDA, hs-CRP, testosterone and low-density lipid (LDL)(p<0.05) and, insignificant negative correlation with high-density lipoprotein(HDL), (p>0.05). The current study demonstrated mounting evidence to support the role of smoking in the pathophysiology of BPH through elevation levels of inflammatory and oxidative stress biomarkers in sera of BPH patients.

Keywords

Benign prostate hyperplasia Interleukin Oxidative stress Smoking.
Al-Barzinj, R. M. G. T. (2020). Estimation levels of prostate-specific antigen, interleukin-8, oxidative stress and some inflammatory markers in sera of benign prostatic hyperplasia patients who have smoking habits as a risk factor. Cellular and Molecular Biology, 66(7), 124–130. https://doi.org/10.14715/cmb/2020.66.7.19
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C et al. Management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). European Association of Urology 2019.
  2. Foster H E, Dahm P, Kohler TS, Lerner LB, Parsons J K, Wilt T J & Mcvary K T. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Amendment. The Journal of urology 2019; 202: 592-598.
  3. Madersbacher S, Sampson N & Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology 2019; 65: 458-464.
  4. LA Vignera S, Condorelli R, Russo G, Morgia G & Calogero A. Endocrine control of benign prostatic hyperplasia. Andrology 2016; 4: 404-411.
  5. Velonas V M, Woo HH, Remedios C G D & Assinder S J. Current status of biomarkers for prostate cancer. International journal of molecular sciences 2013; 14: 11034-11060.
  6. Lilja H. Biology of prostate-specific antigen. Urology 2003; 62: 27-33.
  7. Haythorn M R & Ablin R J. Prostate-specific antigen testing across the spectrum of prostate cancer. Biomarkers in medicine 2011; 5: 515-526.
  8. Lotti F, Maggi M. Interleukin 8 and the male genital tract. Journal of reproductive immunology. 2013 Nov 1;100(1):54-65.
  9. Chiang B J, Kuo H C & Liao C H. Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation? 2019; Toxins; 11: 547.
  10. Banerjee PP, Banerjee S, Brown T R & Zirkin B R. Androgen action in prostate function and disease. American journal of clinical and experimental urology 2018; 6: 62.
  11. Aycicek A & Ipek A. Maternal active or passive smoking causes oxidative stress in cord blood. European journal of pediatrics 2008; 167:81-85.
  12. Sánchez-Rodrí­guez M A& Mendoza-Núñez V M. Oxidative Stress Indexes for Diagnosis of Health or Disease in Humans. Oxidative Medicine and Cellular Longevity 2019.
  13. Palapattu GS, Sutcliffe S, Bastian p J, Platz E A, DE Marzo AM, Isaacs WB & Nelson W G. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005;26: 1170-1181.
  14. Sciarra A, DI Silverio F, Salciccia S, Gomez A M A, Gentilucci A & Gentile V. Inflammation and chronic prostatic diseases: evidence for a link? European urology 2007; 52: 964-972.
  15. Meagher E A & Fitzgerald G A. Indices of lipid peroxidation in vivo: strengths and limitations. Free Radical Biology and Medicine 2000; 28:1745-1750.
  16. Klein E A, Casey G & Silverman R. Genetic susceptibility and oxidative stress in prostate cancer: integrated model with implications for prevention. Urology 2006; 68: 1145-1151.
  17. Matt GE, Quintana PJ, Destaillats H, Gundel LA, Sleiman M, Singer BC, Jacob III P, Benowitz N, Winickoff JP, Rehan V, Talbot P. Thirdhand tobacco smoke: emerging evidence and arguments for a multidisciplinary research agenda. Environmental health perspectives 2011;119(9):1218-26.
  18. Costenbader K & Karlson E. Cigarette smoking and autoimmune disease: what can we learn from epidemiology? Lupus2006; 15: 737-745.
  19. WHO, Body mass index, 2000.
  20. Kucukdurmaz F, Efe E, í‡elik A, DAGLI H, Kilınc M & Resim S. Evaluation of serum prolidase activity and oxidative stress markers in men with BPH and prostate cancer. BMC urology 2017; 17:116.
  21. Tyagi P, Motley SS, Kashyap M, Pore S, Gingrich J, Wang Z, Yoshimura N, Fowke JH. Urine chemokines indicate pathogenic association of obesity with BPH/LUTS. International urology and nephrology 2015;47(7):1051-8.
  22. Aryal M, Pandeya A, Bas B, Lamsal M, Majhi S, Pandit R, Agrawal C, Gautam N& Baral N. Oxidative stress in patients with benign prostate hyperplasia. JNMA; J Nepal Medical Association 2007; 46: 103-106.
  23. Veltri R W, Miller MC, Zhao G, NG A, Marley G M, Wright JR G L, Vessella R L & Ralph D. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology 1999; 53:139-147.
  24. Schauer I G, Ressler S J, Tuxhorn J A, Dang T D & Rowley D R. Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology 2008; 72: 205-213.
  25. Agnihotri S, Mittal RD, Kapoor R & Mandhani A. Asymptomatic prostatic inflammation in men with clinical BPH and erectile dysfunction affects the positive predictive value of prostate-specific antigen. Urologic Oncology: Seminars and Original Investigations. Elsevier 2014: 946-951.
  26. Malati T, Kumari GR, Murthy PV, Reddy CR, Prakash BS. Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate. Indian Journal of Clinical Biochemistry. 2006 Mar 1;21(1):34.
  27. Merendino R A, Salvo F, SAIJA A, DI Pasquale G, Tomaino A, Minciullo P L, Fraccica G & Gangemi S. Malondialdehyde in benign prostate hypertrophy: a useful marker?. Mediators of inflammation 2003; 12:127-128.
  28. Kucukdurmaz F, Efe E, í‡elik A, Dagli H, Kılınc M & Resim S. Evaluation of serum prolidase activity and oxidative stress markers in men with BPH and prostate cancer. BMC urology 2017;17: 116.
  29. Arif M, Arif T, Omer A & Ahmed O. MDA as A Bio-Marker for Benign Prostatic Hyperplasia in Pakistani Population. Cancer Case Reports 2019; 1: 1-6.
  30. Hung SF, Chung SD, Kuo HC. Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia. PloS one 2014;9(1).
  31. Fibbi B, Penna G, Morelli A, Adorini L & Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. International journal of andrology 2010; 33: 475-488.
  32. Macoska J A. Chemokines and BPH/LUTS. Differentiation 2011; 82: 253-260.
  33. Kramer G, Mitteregger D & Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? European urology2007; 51: 1202-1216.
  34. Castro P, Xia C, Gomez L, Lamb D J & Ittmann M. Interleukin"8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. The Prostate 2004; 60: 153-159.
  35. Savas M, Verit A, Ciftci H, Yeni E, Aktan E, Topal U & Erel O. Oxidative Stress in BPH. JNMA J Nepal Medical Association 2009; 48: 41-45.
  36. Aydin A, Arsova-Sarafinovska Z, Sayal A, Eken A, Erdem O, Erten K, í–zgök Y & Dimovsk A. Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Clinical biochemistry 2006; 39: 176-179.
  37. Gecit I, Meral I, Aslan M, Kocyigit A, Celik H, Taskı N A, Kaba M, Pirincci N, Gunes M & Taken K. Peripheral mononuclear leukocyte DNA damage, plasma prolidase activity, and oxidative status in patients with benign prostatic hyperplasia. Redox Report 2015; 20: 163-169.
  38. Gervaix A, Galetto-Lacour A, Gueron T, Vadas L, Zamora S, Suter S, Girardin E. Usefulness of procalcitonin and C-reactive protein rapid tests for the management of children with urinary tract infection. The Pediatric infectious disease journal. 2001 May 1;20(5):507-11.
  39. Vassalle C, Lubrano V, L'abbate A & Clerico A. Determination of nitrite plus nitrate and malondialdehyde in human plasma: analytical performance and the effect of smoking and exercise. Clinical chemistry and laboratory medicine 2002; 40: 802-809.
  40. Hellermann GR, Nagy SB, Kong X, Lockey RF, Mohapatra SS. Mechanism of cigarette smoke condensate-induced acute inflammatory response in human bronchial epithelial cells. Respiratory research. 2002 Dec;3(1):15.
  41. Serdar Z, Dirican M, Serdar A, Sarandöl E, Yeşilbursa D & Tokullugil A. Investigation of the effects of smoking on lipid peroxidation and antioxidants in patients with coronary artery disease. Türkiye Klinikleri. J Med Sci 1999; 19: 266-74.
  42. Strzelak A, Ratajczak A, Adamiec A & Feleszko W. Tobacco smoke induces and alters immune responses in the lung triggering inflammation, allergy, asthma and other lung diseases: a mechanistic review. International journal of environmental research and public health 2018; 15: 1033.
  43. Sopori M. Effects of cigarette smoke on the immune system. Nature Reviews Immunology 2002;2: 372-377.
  44. DE Lema G P, Maier H, Nieto E, Vielhauer V, Luckow B, Mampaso F & Schlöndorff D. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. Journal of the American Society of Nephrology 2001; 12: 1369-1382.
  45. Vignozzi L, Morelli A, Sarchielli E, Comeglio P, Filippi S, Cellai I, Maneschi E,
  46. Serni S, Gacci M, Carini M, Piccinni MP. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. Journal of Endocrinology 2012 Jan 1;212(1):71.
  47. Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S, Maggi M. Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. International journal of endocrinology 2014;2014.
  48. Bhattacharya K, Sengupta P, Dutta S, Karkada IR. Obesity, systemic inflammation and male infertility. Chemical Biology Letters 2020 Mar 16;7(2):92-8.
  49. Merendino R A, Salvo F, Saija A, DI Pasquale G, Tomaino A, Minciullo P L, Fraccica G, Gangemi S. Malondialdehyde in benign prostate hypertrophy: a useful marker? Mediators of inflammation 2003;12:127-128.
  50. Elkady A, Tawfik S. Anti-inflammatory role of piperine against rat lung tissue damage induced by gamma-rays. Int J Radiat Res. 2018; 16 (1) :75-84.
  51. Korani S, Kazemi B, Haghighi A, Nikpoor AR, Bandehpour M. The Effect of Human Recombinant Tumor Necrosis Factor Receptor-2 on Reducing Inflammatory of Collagen -Induced Arthritis in Balb/c Mice. Iran J Biotechnol. Jan 2019; 17(1): e2153.
  52. Azab K S, Thabet N, Abdel Ghaffar A, Osman A, El-Batal A. Nano selenium-lovastatin mixture modulate inflammatory cascade in arthritic irradiated model. Int J Radiat Res. 2015; 13 (4) :305-316
  53. Bordbar M, Darvishzadeh R, Pazhouhandeh M, Kahrizi D. An overview of genome editing methods based on endonucleases. Mod Genet J 2020; 15(2): 75-92.
  54. Ghanooni S, Dadkhah A, Fatemi F, Zolfaghari M. Evaluation of γ-irradiation treatment on the antibacterial activities of Mentha piperita L. essential oils in vitro and in vivo systems (CLP inflammatory model). Int J Radiat Res. 2015; 13 (3) :281-286.
  55. Bagri P, Singh D, Kumari P, Kumari S, Beniwal S, Kumar H. Successful treatment of inflammatory myofibroblastic tumor by surgical resection and radiotherapy: A case report. Int J Radiat Res. 2014; 12 (4) :387-390.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 1060 Download : 608